In This Section

Program

Please note that this meeting will take place as an in-person event in Tampa and will not live-stream content for virtual participation. The meeting content will be recorded and made available as an on-demand program after the conference. Please see the REGISTRATION page for details. 

All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise.  Program is subject to change. 

[R] – Remote Presentation
*-Short talk selected from proffered abstracts

Monday, March 14, 2022

Welcome and Keynote Lectures

Tuesday, March 15, 2022

Plenary Session 1: Longitudinal Dissection of Resistance Evolution
Panel Discussion: Genetic, Epigenetic and Functional Heterogeneity in Cancer: Which One(s) Can We Call Evolution?
Plenary Session 2: Clonal Evolution, Part I
Plenary Session 3: Generation of Genomic and Epigenomic Diversity

Wednesday, March 16, 2022

Plenary Session 4: Microenvironmental Selection
Plenary Session 5: Mechanisms and Dynamics of Resistance Emergence, Part I
AACR Cancer Evolution Working Group Session
Plenary Session 5: Mechanisms and Dynamics of Resistance Emergence, Part II
Plenary Session 5: Mechanisms and Dynamics of Resistance Emergence, Part II (continued)

Thursday, March 17, 2022

Plenary Session 6: Evolutionary Guided (Adaptive) Therapy to Prevent Emergence of Resistance
Plenary Session 7: Clonal Evolution, Part II

MONDAY, March 14, 2022

Welcome and Keynote Lectures
SESSION CHAIR: ANDRIY MARUSYK, H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, TAMPA, FLORIDA
5:30-7:15 p.m.

Welcome from Cochairs and Introduction of Cancer Evolution Working Group
Robert J. Gillies, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida
Andriy Marusyk, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida
Cancer Evolution Working Group Representative, to be announced

Harnessing evolutionary dynamics for control and cure of metastatic cancers
Robert A. Gatenby, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida

Cancer evolution, immune evasion, and metastasis
Charles Swanton, The Francis Crick Institute and UCL Cancer Institute, London, United Kingdom

Opening Reception
7:15-9 p.m.                    

TUESDAY, March 15, 2022

Breakfast
7-8 a.m.
Plenary Session 1: Longitudinal Dissection of Resistance Evolution
SESSION CHAIR: MARCO Gerlinger, Barts Cancer Institute, Queen Mary University of London, United Kingdom
8-10 a.m.

Darwinian and non-Darwinian evolution of cancer drug resistance
Marco Gerlinger

Deciphering clonal evolution under chemotherapy in high-risk neuroblastoma using patient derived models*
Natalie Andersson, Lund University Faculty of Medicine, Lund, Sweden

Tracking population heterogeneity and chemoresistance with functionalized cell barcodes 
Amy Brock, The University of Texas at Austin, Austin, Texas

Advanced melanoma exhibits a diversity of evolutionary routes to lethality*
Alexander Coulton, University College London, London, United Kingdom

Title to be announced
Trever G. Bivona, University of California San Francisco, San Francisco, California

Break
10-10:30 a.m.      
Panel Discussion: Genetic, epigenetic and functional heterogeneity in cancer: which one(s) can we call evolution?
MODERATOR: Alexander R.A. Anderson, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FLORIDA
10:30-11:30 a.m.  

Amy Brock, The University of Texas at Austin, Austin, TX

Robert A. Gatenby, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida

Charles Swanton, The Francis Crick Institute and UCL Cancer Institute, London, United Kingdom

Lunch on own
11:30 a.m.-1:45 p.m.    
Plenary Session 2: Clonal Evolution, Part I
Session Chair: Iñigo Martincorena, Wellcome Sanger Institute, Hinxton, United Kingdom
1:45-3:45 p.m.

Somatic mutation and clonal expansion in normal tissues
Iñigo Martincorena

Integration of clonal composition and tumor heterogeneity reveals novel evolutionary states and intervention targets in ovarian cancer*
Alexandra Lahtinen, University of Helsinki, Helsinki, Finland

Outcompeting cancer in the intestine
Louis M. Vermeulen, Academic Medical Center, Amsterdam, The Netherlands

In vivo tracking of clonal dynamics during UV-induced skin carcinogenesis*
Stanislav Avdieiev, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida

Charting normal and malignant differentiation topologies with single-cell multi-omics
Dan-Avi Landau, Weill Cornell Medicine, New York, New York

Break
3:45-4:15 p.m.
Plenary Session 3: Generation of Genomic and Epigenomic Diversity
SESSION CHAIR: RONG LI, JOHNS HOPKINS UNIVERSITY, BALTIMORE, MARYLAND
4:15-6:15 p.m.

Cancer is a disease of epigenetic stochasticity [R]
Andrew P. Feinberg, Johns Hopkins University, Baltimore, Maryland

TP53 field defects in uterine fluid are associated with ovarian cancer risk*
Rosana Risques, University of Washington, Seattle, Washington

Models of mutagenesis and carcinogenesis by human APOBEC3 enzymes 
Reuben S. Harris, University of Minnesota, Minneapolis, Minnesota

An emerging role for inflammation-associated alveolar intermediate cells in early phenotypic development of KRAS-mutant lung adenocarcinoma*
Ansam Sinjab, UT MD Anderson Cancer Center, Houston, Texas

Stress-induced mutations, the DNA damageome and cancer
Susan M. Rosenberg, Baylor College of Medicine, Houston, Texas

POSTER SESSION A / RECEPTION
6:30-8 p.m.           

WEDNESDAY, March 16, 2022

Breakfast
7-8 a.m.            
Plenary Session 4: Microenvironmental Selection
Session Chair: Carlo C. Maley, Arizona State University, Tempe, Arizona
8-10 a.m.

Aging, tissue ecology, and the evolution of cancer within us 
James V. DeGregori, University of Colorado, Aurora, Colorado

Homotypic cell-cell fusion in TNBC cells alters therapeutic sensitivity*
Andrea Gardner, University of Texas at Austin, Austin, Texas

Genetic heterogeneity and tumor microenvironment in glioblastoma
Michalina Janiszewska, The Scripps Research Institute, Jupiter, Florida

Immunosuppressive niche engineering at the onset of human colorectal cancer*
Chandler Gatenbee, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida

Insights from comparative oncology
Carlo C. Maley

Break
10-10:30 a.m.
Plenary Session 5: Mechanisms and Dynamics of Resistance Emergence, Part I
SESSION CHAIR: ANDRIY MARUSYK, H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, TAMPA, FLORIDA
10:30 a.m.-12:15 p.m.

Exploring how competition can be leveraged to improve adaptive therapy in metastatic prostate cancer
Renee Brady-Nicholls, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida

Investigating dynamics of the mitochondrial network in triple negative breast cancer chemotherapy resistance* [R]
Gloria V. Echeverria, Baylor College of Medicine, Houston, Texas

Evolutionary Tumor Board: Implementing dynamic personalized therapy using evolutionary theory and mathematical modeling for clinical decision support*
Mark Robertson-Tessi, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida

Targeting Cellular Plasticity-driven Metabolic Adaptation to Overcome Chemoresistance in GBM*
Atique U. Ahmed, Northwestern University, Chicago, Illinois

Resistance to ALK-targeting therapies in lung cancers is acquired through complex, context specific evolutionary trajectories
Andriy Marusyk

AACR Cancer Evolution Working Group Session (Lunch Provided)
12:30-2 p.m.

CO-CHAIRS:

Charles Swanton, The Francis Crick Institute and UCL Cancer Institute, London, United Kingdom

Frank H. Laukien, Harvard University, Cambridge, Massachusetts

SPEAKERS:

Susan M. Rosenberg, Baylor College of Medicine, Houston, Texas

Kenneth J. Pienta, Johns Hopkins University School of Medicine, Baltimore, Maryland

Robert A. Gatenby, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida

Nicholas E. Navin, University of Texas MD Anderson Cancer Center, Houston, Texas

Plenary Session 5: Mechanisms and Dynamics of Resistance Emergence, Part II
SESSION CHAIR: Sydney Shaffer, University of Pennsylvania, Philadelphia, Pennsylvania
2-5 p.m.

The polyaneuploid cancer cell state as a mediator of therapeutic resistance
Kenneth J. Pienta, Johns Hopkins School of Medicine, Baltimore, Maryland

Genetic and immune landscape evolution defines subtypes of MMR deficient colorectal cancer*
Benjamin R. Challoner, The Institute of Cancer Research, London, United Kingdom

Single-cell analysis of drug resistance, cellular memory, and plasticity in cancer
Sydney Shaffer

Break
3:15-3:45 p.m.                    
Plenary Session 5: Mechanisms and Dynamics of Resistance Emergence, Part II (continued)
3:45-5 p.m.

Resolving the paradigm of the pre-existing resistance to targeted therapy, and the fitness costs associate with resistance: In vitro and theoretical evidence using an evolutionary game theoretic approach
Jacob G. Scott, Cleveland Clinic, Cleveland, Ohio

Oct4 and Sox2 induce cellular transition of glioma stem cells to an immune suppressive, regulatory T cell-like state*
Hernando Lopez-Bertoni, Johns Hopkins School of Medicine, Baltimore, Maryland

Dynamics of response and resistance to cancer therapy [R]
Ivana Bozic, University of Washington, Seattle, Washington

Poster Session B / Reception
5-7 p.m.
EVENING OFF / Dinner on Own
7 p.m.

THURSDAY, March 17, 2021

Breakfast
7-8 a.m.
Plenary Session 6: Evolutionary Guided (Adaptive) Therapy to Prevent Emergence of Resistance
SESSION CHAIR: Alexander R.A. Anderson, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FLorida
8-10 a.m.

Karyotype heterogeneity driving evolutionary adaptation
Rong Li, Johns Hopkins University, Baltimore, Maryland

Design and construction of evolutionary-guided “selection gene drive” therapy*
Scott Leighow, Penn State University, University Park, Pennsylvania

Exploiting immune surveillance to target colorectal cancer evolution and mutability
Alberto Bardelli, Candiolo Cancer Institute IRCCS, University of Turin, Italy

Developing adaptive therapy to suppress the evolution of treatment resistance in high-grade serous ovarian cancer*
Helen Hockings, Barts Cancer Institute, London, United Kingdom

Selection for a glycolytic phenotype
Mehdi Damaghi, Stony Brook University, Stony Brook, New York

Break
10-10:15 a.m.     
Plenary Session 7: Clonal Evolution, Part II
SESSION CHAIR: CHRISTINA CURTIS, STANFORD UNIVERSITY,  STANFORD, CALIFORNIA
10:15 a.m.-12:15 p.m.  

The role of the epigenome and phenotypic plasticity in colorectal cancer evolution
Trevor Graham, Institute of Cancer Research, London, United Kingdom

The spatial landscape of clonal somatic mutations in benign and malignant tissue*
Alastair Lamb, University of Oxford, Oxford, United Kingdom

Decoding breast cancer evolution with single cell genomics
Nicholas E. Navin, The University of Texas MD Anderson Cancer Center, Houston, Texas

Progression and regression dynamics of bivalve transmissible neoplasia in the soft-shell clam (Mya arenaria) after both natural and experimental exposure*
Rachael Giersch, Pacific Northwest Research Institute, Seattle, Washington

Charting genotype to phenotype maps of tumorigenesis
Christina Curtis

Closing Remarks
12:15 p.m.        

James V. DeGregori, University of Colorado, Aurora, Colorado